• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview of the talk
3. Global TB control: challenges
4. Source of healthcare - South-East Asia
5. Non-qualified health provider in India
6. A pharmacy in Yangon
7. Source of healthcare - Sub-Saharan Africa
8. TB drugs sold in the private market
9. Why engage private care providers?
10. The TB programme in mixed health systems
11. Public-private mix: a role for every provider
12. The public-private mix model
13. Practicing PPM
14. Documentation: journal papers on PPM for TB
15. Evidence: feasibility
16. Evidence: effectiveness
17. Cost-effectiveness
18. Evidence
19. WHO's stop TB strategy
20. Advocacy: global PPM subgroup
21. Working approaches
22. Private TB clinic in Myanmar
23. PPM contribution to case notifications 2010
24. PPM contribution to case notifications 2011
25. Enhancing PPM with new technology
26. PPM guidance and tools
27. PPM scale up tool-kit
28. Challenges and approaches to scaling up
29. Acknowledgments

Topics Covered

• Challenges of global TB control
• Source of healthcare in South-East Asia and Sub-Saharan Africa
• Non-qualified health providers
• TB drugs sold in the private market
• Why engage private care providers?
• The public-private mix model
• WHO's stop TB strategy
• PPM contribution to case notifications in 2010 and 2011
• Enhancing PPM with new technology
• PPM guidance and tools
• Challenges and approaches to scaling up

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on March 28, 2013
• Archived on May 31, 2022

Financial Disclosures

• Dr. Mukund Uplekar has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.